发酵来源的抗肿瘤药物（αS，5S）-α-氨基-3-氯-4,5-二氢-5-异恶唑乙酸（AT-125）的生化药理学研究 - Suppr | 超能文献

Studies of the biochemical pharmacology of the fermentation-derived antitumor agent, (alpha S, 5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125).

作者信息

Neil G L, Berger A E, Bhuyan B K, Blowers C L, Kuentzel S L

出版信息

Adv Enzyme Regul. 1978;17:375-98. doi: 10.1016/0065-2571(79)90023-2.

DOI:10.1016/0065-2571(79)90023-2

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Studies of the biochemical pharmacology of the fermentation-derived antitumor agent, (alpha S, 5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125).发酵来源的抗肿瘤药物（αS，5S）-α-氨基-3-氯-4,5-二氢-5-异恶唑乙酸（AT-125）的生化药理学研究

Adv Enzyme Regul. 1978;17:375-98. doi: 10.1016/0065-2571(79)90023-2.

2

Biochemical and pharmacological effects of the fermentation-derived antitumor agent, (alphaS,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125).发酵衍生抗肿瘤剂（αS，5S）-α-氨基-3-氯-4,5-二氢-5-异恶唑乙酸（AT-125）的生化和药理作用

Cancer Res. 1979 Mar;39(3):852-6.

3

L-[alphaS, 5S]-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (NSC-163501): a new amino acid antibiotic with the properties of an antagonist of L-glutamine.L-[αS, 5S]-α-氨基-3-氯-4,5-二氢-5-异恶唑乙酸（NSC-163501）：一种具有L-谷氨酰胺拮抗剂特性的新型氨基酸抗生素。

Cancer Chemother Rep. 1975 May-Jun;59(3):481-91.

4

Mechanism of resistance of a variant of P388 leukemia to L-(alpha S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).P388白血病一种变体对L-(αS,5S)-α-氨基-3-氯-4,5-二氢-5-异恶唑乙酸（阿西维辛）的耐药机制。

Cancer Res. 1985 Jan;45(1):207-12.

5

The inhibition of gamma-glutamyl transpeptidase from human pancreatic carcinoma cells by (alpha S,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125; NSC-163501).(αS,5S)-α-氨基-3-氯-4,5-二氢-5-异恶唑乙酸（AT-125；NSC-163501）对人胰腺癌细胞γ-谷氨酰转肽酶的抑制作用

Res Commun Chem Pathol Pharmacol. 1980 Jan;27(1):175-82.

6

A new antitumor agent, (alphas, 4s, 5r)-alpha-amino-3-chloro-4-hydroxy-4,5-dihydro-5-isoxazoleacetic acid (NSC-176324): preliminary evaluation against L 1210 mouse leukemia in vivo.一种新型抗肿瘤药物，（αS，4S，5R）-α-氨基-3-氯-4-羟基-4,5-二氢-5-异恶唑乙酸（NSC-176324）：对L 1210小鼠白血病的体内初步评价

Cancer Chemother Rep. 1974 Nov-Dec;58(6):935-7.

7

Acivicin. An antitumor antibiotic.阿西维辛。一种抗肿瘤抗生素。

Cancer Clin Trials. 1981 Fall;4(3):327-30.

8

Enhanced effect of an L-glutamine antagonist, L-(alphaS,5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid, by Acinetobacter L-glutaminase-L-asparaginase.不动杆菌L-谷氨酰胺酶-L-天冬酰胺酶对L-谷氨酰胺拮抗剂L-(αS,5S)-α-氨基-3-氯-4,5-二氢-5-异恶唑乙酸的增强作用。

Cancer Treat Rep. 1979 Jun;63(6):1109-14.

9

Collateral sensitivity to N-(phosphonacetyl)-L-aspartic acid in a line of P388 leukemia cells selected for resistance to L-(alpha S, 5S)-alpha-amino-3- chloro-4,5-dihydro-5-isoxazoleacetic acid (acivicin).对N-（膦酰基乙酰基）-L-天冬氨酸的 collateral 敏感性在一株对L-（αS，5S）-α-氨基-3-氯-4,5-二氢-5-异恶唑乙酸（阿西维辛）产生抗性的P388白血病细胞系中。（注：“collateral”这里可能是专业术语“旁系的”之类意思，具体准确意思需结合专业知识进一步确定）

Cancer Res. 1983 Apr;43(4):1598-601.

10

Mechanism of inactivation of glutamine amidotransferases by the antitumor drug L-(alpha S, 5S)-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (AT-125).抗肿瘤药物L-(αS,5S)-α-氨基-3-氯-4,5-二氢-5-异恶唑乙酸（AT-125）使谷氨酰胺酰胺转移酶失活的机制

J Biol Chem. 1980 Jul 25;255(14):6734-8.

引用本文的文献

1

Rethinking glutamine metabolism and the regulation of glutamine addiction by oncogenes in cancer.重新审视癌症中谷氨酰胺代谢及癌基因对谷氨酰胺成瘾的调控

Front Oncol. 2023 Mar 7;13:1143798. doi: 10.3389/fonc.2023.1143798. eCollection 2023.

2

Phase II trial of continuous drug infusions in advanced ovarian carcinoma: acivicin versus vinblastine.

Invest New Drugs. 1989 Jul;7(2-3):255-60. doi: 10.1007/BF00170870.